India does not allow patents on pharmaceuticals.[1] As a result, they have an excellent market for generics, but new medicine is 6-8 years behind the rest of the world.

https://link.springer.com/chapter/10.1007/978-981-13-8102-7_...

Not always, the cancer drug lenalidomid (Revlimid) is around 20 000$ for 21 pills in the US, the indian generica is around 200$.